OncoMatch/Clinical Trials/NCT05924997
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Is NCT05924997 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies adebrelimab, camrelizumab plus apatinib for advanced hepatocellular carcinoma.
Treatment: adebrelimab, camrelizumab plus apatinib — This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IV
Patients with hepatocellular carcinoma diagnosed by EASL/AASLD diagnostic criteria, histopathology or cytology are not suitable for surgery or local treatment, or progress after surgery and/or local treatment
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Never received any systematic treatment for HCC before
Cannot have received: anti-PD-1 therapy
Previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1
Cannot have received: anti-angiogenesis targeted therapy (apatinib)
previously received apatinib therapy
Lab requirements
Blood counts
Hemoglobin ≥ 90g/L; Neutrophil count ≥ 1.5×10^9/L; Platelet count ≥ 50×10^9/L
Kidney function
Creatinine ≤1.5x ULN or Cr clearance rate > 50mL/min
Liver function
Serum albumin ≥ 29g/L; ALT and AST ≤2.5x ULN; TBIL ≤1.5x ULN; Child-Pugh A or B
Cardiac function
LVEF ≥ 60%
The functions of major organs are basically normal... see full text for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify